Shots:

• Alvotech will take care of development and supply of the product while Cipla Gulf- subsidiary of Cipla will be responsible for Alvotech’s AVT02 registration and commercialization
• The agreement will allow Alvotech to have access for Cipla’s strong commercial network in selected emerging markets enabling patients with high-quality biosimilars
• Alvotech’s AVT02 is a mAb and a biosimilar to AbbVie’s Humira involved in neutralizing TNF-α targeted for several autoimmune diseases including RA- AS- PP- Psoriatic Arthritis- UC- CD and is currently evaluated in P-III trial with its BLA submission with US FDA and EMA in H1’20

Click here to read full press release/ article | Ref: Cipla | Image: Behance